The Rationalization of EAPs for Small Biotech

• Getting to Phase 3 – The story of WinSantTor
• When Innovation is not always a good thing
• Going from unfundable to a precommercial company in three months
• The difference of Right to Try and Compassionate Use
• Navigating the evolving Expanded Access Programs globally
• How Right to Try will disrupt Innovation for other biotechs

Speakers:

Stanley Kim

Chief Executive Officer

WinSanTor Inc.